Bifidobacterium lactis reduced diarrhea durationAdjudicative efficacy of Bifidobacterium animalis subsp. lactis BLa80 in treating acute diarrhea in children: a randomized, double-blinded, placebo-controlled study.
We explored the impact of Bifidobacterium animalis subsp. lactis BLa80 on diarrhea in young children through a well-structured, randomized, double-blinded, placebo-controlled study.
Our findings show that children receiving the probiotic experienced a significantly shorter duration of diarrhea and a higher recovery rate compared to those given a placebo.
Notably, we also observed beneficial changes in gut microbiome composition and gene functions that promote immune response.
This evidence suggests that Bifidobacterium lactis can effectively support recovery from acute diarrhea in children.
Read More
Lactococcus lactis shows immunization potentialA Lactococcus lactis-vectored oral vaccine induces protective immunity of mice against enterotoxigenic Escherichia coli lethal challenge.
We explored the effectiveness of a live recombinant Lactococcus lactis vaccine designed to combat enterotoxigenic Escherichia coli, a major cause of diarrhea. The study involved administering the vaccine to mice, who then showed strong immune responses, such as increased antibody production and T cell activation.
After being challenged with ETEC, these mice exhibited complete protection from the disease. This suggests that the Lactococcus lactis vaccine could be a promising oral vaccine candidate against E. coli-related diarrhea.
Read More
Probiotics aid IBS-D treatment outcomesTwo Lactobacilli strains as adjuvant therapy in the management of irritable bowel syndrome: a randomized control trial.
We explored the impact of Lactobacillus acidophilus and L. plantarum on patients suffering from diarrhea-predominant irritable bowel syndrome (IBS-D). In a randomized, single-blinded clinical trial of 100 patients, some received standard IBS treatment alone while others added probiotics to their therapy.
After 12 weeks, both groups saw improvements, but those who took probiotics reported significantly better outcomes. Patients using probiotics experienced greater reductions in IBS symptoms, achieving near complete relief, while some on standard treatment still faced moderate symptoms. This suggests probiotics could enhance IBS management.
Read More
Probiotics aid IBS-D treatment outcomesTwo Lactobacilli strains as adjuvant therapy in the management of irritable bowel syndrome: a randomized control trial.
We explored the impact of Lactobacillus acidophilus and L. plantarum on patients suffering from diarrhea-predominant irritable bowel syndrome (IBS-D). In a randomized, single-blinded clinical trial of 100 patients, some received standard IBS treatment alone while others added probiotics to their therapy.
After 12 weeks, both groups saw improvements, but those who took probiotics reported significantly better outcomes. Patients using probiotics experienced greater reductions in IBS symptoms, achieving near complete relief, while some on standard treatment still faced moderate symptoms. This suggests probiotics could enhance IBS management.
Read More
Probiotics effectively manage diarrheaMultistrain Probiotics Alleviate Diarrhea by Modulating Microbiome-Derived Metabolites and Serotonin Pathway.
We aimed to understand how a mix of probiotics called Sensi-Biome affects diarrhea triggered by gut imbalances. In our study, this probiotic blend was tested on rats suffering from acid-induced diarrhea.
We observed improved stool moisture, intestinal movement, and overall gut health, specifically in one of the dosage groups. Notably, the probiotics also helped balance serotonin levels and reduced inflammation.
This shows that Sensi-Biome can indeed help manage diarrhea by impacting gut health and related metabolic pathways.
Read More